Introduction
============

Alzheimer Disease (AD) is a progressive neurological degenerative disease and the most common form of dementia. It accounts for 50%-60% of dementia cases and affects quality of life in elderly people.^[@B1]-[@B3]^ According to the Alzheimer's Disease International, it is estimated that there are currently 30 million people with dementia in the world which will increase to 100 million by 2050.^[@B4]^ It is also estimated that almost 13% of people over 65 years are affected, and its prevalence increases with age, so that 1% of people with 65 years old and younger, and 40% of persons aged over 90 years suffer from this disease.^[@B5]^ Less than 1% of all patients with AD experience early onset (before the age of 60-65 years) and 60% of the early AD is familial.^[@B6],[@B7]^ It is proved that no environmental factors (e.g. head injury, viruses, toxins, lower education level) have a direct role in the pathogenesis of AD. Therefore, it seems that AD late onset results from unknown environmental factors on a predisposed genetic background.^[@B8],[@B9]^

There are about 100 genes linked to AD including apolipoprotein E (ApoE), a risk factor for AD that has attracted much attention.^[@B10],[@B11]^ ApoE gene, located on chromosome 19, is the genetic source of the most common form of AD with late onset. This gene is in the form of three alleles of ε~2~, ε~3~, and ε~4~, and six genotypes of ε~2~ε~3~, ε~2~ε~2~, ε~3~ε~3~, ε~2~ε~4~, ε~3~ε~4~, and ε~4~ε~4~.^[@B12]^ ApoE protein is expressed by all tissues, and is effective in the regulation of cell function of different tissues and organs in addition to lipid transfer.^[@B13]^ Human and animal studies clearly have shown that ApoE isoforms differentially affect the assembly and clean-up of β-amyloid. Evidence from genetic, pathologic and functional studies has shown that the imbalanced production and clearance of β-amyloid peptide in the brain leads to its accumulation, and eventually nerve degeneration and dementia.^[@B2],[@B6]^ Many studies on genome have confirmed that ε~4~ allele of ApoE gene is the strongest genetic risk factor for AD. This allele is associated with an increased risk of both early and late AD. β-amyloid deposits in the form of senile plaques in ApoE ε~4~ carriers as compared to non-carriers.^[@B14]^ Therefore, ApoE genotypes strongly influence β-amyloid deposits in the form of senile plaques and lead to cerebral amyloid angiopathy.^[@B15]^ Clinical autopsy-based meta-analysis studies have shown that the risk of AD in individuals with one copy of ε~4~ allele (ε~3~ε~4~, ε~2~ε~4~) or two copies (ε~4~ε~4~) was higher among whites as compared to patients with genotype ε~3~ε~3.~^[@B16]^ Although ε~3~ allele is the most common one, various studies have shown that ε~4~ allele in people with late family history and sporadic AD, in comparison with control group, has a higher frequency. ε~3~ allele has a moderate effect, and its impact on the disease pathology is a basic comparison for ε~4~ and ε~2~ isoforms due to a very high frequency. ε~2~ allele of the ApoE gene has a lower frequency and possesses protective effects against AD.^[@B12]^

In the view of the above-mentioned facts, the purpose of conducting this case-control study is to evaluate the association of ApoE polymorphism with the susceptibility to AD in Iranian population.

Materials and Methods
=====================

The case-control study was conducted on 70 cases and 100 healthy controls. A questionnaire including information such as age, sex, family history of AD, and the race was used. All subjects were native Iranian living in the north of Iran, Guilan province. Patients' mean age ± standard deviation (SD) was 77.1 ± 9.4, ranging from 65 to 89 years. Patients, diagnosed with AD, were recruited from 21 March to 22 September 2015, at Imam Reza Clinic of Guilan, Rasht. Identification and diagnosis of AD were performed based on National Institute of Neurological Disorders and Stroke-Alzheimer\'s Disease and Related Disorders Association (NINCDS-ADRDA) criteria. Patients diagnosed with Parkinson\'s disease or Parkinsonism at any time before the onset of dementia, patients with a history of stroke, history of alcohol abuse, or conclusive clinical history of schizophrenia or schizoaffective disorder before dementia onset were excluded from the study. Controls with the mean age of 74.7 ± 10.3 years (ranging from 65 to 87 years) were nonrelated and healthy individuals. Cases and controls were matched for age, and there were no significant differences between two groups (case and control) in terms of sex, race and family history of AD (P \> 0.050). The characteristics of the cases and controls are shown in [table 1](#T1){ref-type="table"}. Informed consent for the genetic analysis was obtained from all participants. The study was conducted in accordance with the Declaration of Helsinki regarding the use of human samples.

For each sample, 1 ml blood was collected by venipuncture and drawn into Ethylenediaminetetraacetic acid (EDTA)-K3 coated tubes. Genomic deoxyribonucleic acid (DNA) was extracted from peripheral leukocytes using extraction kit following standard procedures. Extracted DNAs were frozen at -20 °C until the time of doing the molecular analysis.

###### 

Characteristics of cases and controls

  **Characteristics**              **Case (n = 70)**   **Control (n = 100)**   **P** [\*](#TFN1){ref-type="table-fn"}   
  -------------------------------- ------------------- ----------------------- ---------------------------------------- -------
  Sex \[n (%)\]                    Man                 32 (45.7)               47 (47.0)                                0.990
  Woman                            38 (54.3)           53 (53.0)                                                        
  Family history of AD \[n (%)\]   Yes                 19 (27.1)               23 (23.0)                                0.660
  No                               51 (72.9)           77 (77.0)                                                        
  Race \[n (%)\]                   Gilak               51 (72.9)               74 (74.0)                                0.810
  Talesh                           9 (12.8)            14 (14.0)                                                        
  Turk                             6 (8.6)             5 (5.0)                                                          
  Tat                              4 (5.7)             7 (7.0)                                                          

AD: Alzheimer disease

Chi-square test

Genomic DNA quality was assessed by electrophoresis with 1% agarose gel. The gel was visualized by the gel documentation system.

The ApoE genotypes were determined by tetra-primer amplification-refractory mutation system-polymerase chain reaction (ARMS-PCR). The extracted DNA was used as a template for PCR. Amplifications were carried out using primers designed by Oligo software (version 7.54, Molecular Biology Insights Inc., Cascade, CO, USA). The reaction was performed for all samples after optimization of PCR conditions for amplification of the desired allele. PCR amplifications were carried out in a total volume of 25 µl containing 30 ng genomic DNA, 1x PCR buffer, 1.5 mM MgCl~2~, 0.2 mM deoxynucleotide triphosphate (dNTP), 0.5 mM each primer, and 1.5 U of superTaq DNA polymerase. At the end, PCR products were analyzed by agarose gel electrophoresis, and alleles and genotypes were identified based on the length of the used fragments and primers.

The statistical significance of differences between groups was calculated by the chi-square test. A P of less than 0.050 was considered statistically significant. The odds ratios (OR) and 95% conﬁdence intervals (95% CI) were calculated using logistic regression to estimate the strength of the association between ApoE genetic variation and susceptibility to AD. All statistical analyses were conducted using the MedCalc software (version 12.1).

Results
=======

This case-control study included 70 patients with AD and 100 healthy controls. The distributions of ε~3~ε~3~, ε~3~ε~4~, ε~2~ε~2~, ε~2~ε~4~, ε~4~ε~4~ and ε~2~ε~3~ genotypes among patients were 55.7%, 30.0%, 1.4%, 2.9%, 8.6%, 1.4%, and in the controls were 79.0%, 8.0%, 0%, 1.0%, 1.0%, 11.0%, respectively. The genotype frequencies were significantly different between cases and the controls (P \< 0.001). It was observed that the individuals with ε~4~ε~4~ and ε~3~ε~4~ genotypes had a greater risk of AD compared to others (OR = 12.15, 95% CI: 1.41-104.50, P = 0.020; OR = 5.32, 95% CI: 2.16-13.08, P = 0.003). The allele frequencies of ApoE were 71.4% ε~3~, 3.6% ε~2~ and 25.0% ε~4~ in the AD cases and 88.5% ε~3~, 6.0% ε~2~ and 5.5% ε~4~ in the controls. We observed a significant difference in allele distribution of ApoE between AD patients and the controls (P \< 0.001). In addition, the ε~4~ allele is significantly associated with higher AD risk among the studied population (OR = 5.63, 95% CI: 2.74-11.58, P \< 0.001) ([Table 2](#T2){ref-type="table"}).

###### 

Genotype and allele frequencies of apolipoprotein E (ApoE) and its association with Alzheimer disease (AD)

  **Genotype**   **Case \[n (%)\]**   **Control \[n (%)\]**   **OR (95% CI)**       **P** [\*](#TFN2){ref-type="table-fn"}
  -------------- -------------------- ----------------------- --------------------- ----------------------------------------
  ε~3~ε~3~       39 (55.7)            79 (79.0)               1.00 (Ref)            \-
  ε~4~ε~4~       6 (8.6)              1 (1.0)                 12.15 (1.41-104.50)   0.020
  ε~3~ε~4~       21 (30.0)            8 (8.0)                 5.32 (2.16-13.08)     0.003
  ε~2~ε~2~       1 (1.4)              0 (0)                   6.04 (0.24-151.62)    0.270
  ε~2~ε~4~       2 (2.9)              1 (1.0)                 4.05 (0.36-46.06)     0.260
  ε~2~ε~3~       1 (1.4)              11 (11.0)               0.18 (0.02-1.48)      0.110
  Allele                                                                            
       ε~3~      100 (71.4)           177 (88.5)              1.00 (Ref)            \-
       ε~2~      5 (3.6)              12 (6.0)                0.74 (0.25-2.15)      0.580
       ε~4~      35 (25.0)            11 (5.5)                5.63 (2.74-11.58)     \< 0.001

OR: Odds ratio; CI: Confidence interval

\*Chi-square test

Discussion
==========

Studies in human and transgenic mice have shown that brain β-amyloid levels and amyloid plaque loads are ApoE isoform-dependent, suggesting an important role of ApoE in modulating β-amyloid metabolism, aggregation, and deposition.^[@B17]^ ApoE gene, known to mediate the regulation of cholesterol and triglyceride metabolism, is immunochemically localized to the senile plaques, vascular amyloid, and neurofibrillary tangles of AD.^[@B18]^ Genome-wide association studies confirmed that ε4 allele of APOE is the strongest genetic risk factor for AD.^[@B19]^ To date, no study has investigated the association between the genotypes of ApoE and the AD risk in the Guilan province. The present study evaluated the effect of ApoE variation on AD in the north of Iran, Guilan. Our findings suggest that individuals with ε~4~ε~4~ genotype have the highest risks of developing AD. Moreover, the most frequent genotype was ε~3~ε~3~ in patients and controls in Guilan. Our analysis also confirmed a significant association of the ε~4~ allele with AD.

To date, many epidemiological studies have suggested a relationship between ApoE genetic variations and AD risk. In 2013, Sabbagh, et al. in their study showed that ApoE ε~4~ carriers had a significantly higher percentage of frequentscores for plaques and tangles in comparison with ApoE ε~4~ non-carriers for several brain regions.^[@B12]^ Furthermore, Altmann, et al. showed that APOE ε~4~ confers greater AD risk in women.^[@B20]^ Isbir, et al. in Turkey showed that there was a significantly higher frequency of the ApoE ε~4~ allele in the group of Alzheimer's patients than in control subjects.^[@B21]^ In China, Zhou, et al. studied the relationship between ApoE gene polymorphism and AD in the case group and control group in Uyghurs and Han populations. The distinction was seen in both ethnic groups so that the frequency of ε~3~ε~4~ genotype and ε~4~ allele in case group of Uyghurs and Han were higher than those in the control group. ApoE ε~4~ allele was recognized as a risk factor for AD for both populations.^[@B22]^

Another study conducted by Gavett, et al. showed that more ε~2~ alleles were associated with less AD pathology and, in turn, with less severe dementia. In contrast, more ε~4~ alleles were associated with more pathology and more severe dementia.^[@B23]^ Mino, et al. showed that there was no statistically significant relationship between case group (with AD and dementia) and control group (without AD and dementia) in terms of sex and family history and distribution of ApoE alleles.^[@B24]^ A study conducted in 2014 reported that there is a statistically significant relationship between the types of ApoE and patients' age so that risk alleles, such as ε~4~, decrease the age of onset as 3-6 months.^[@B5]^

ApoE ε~4~ allele frequency varies in different ethnic groups, and the mean has been estimated as 6.5 ± 13% in all groups. It has been reported that the lowest frequency was observed among Chinese and Japanese people (7.4 ± 0.8%), and the highest frequency was found among Sudanese (29%),^[@B21]^ and Finnish people (23-24%).^[@B25]^ Shahsavar, et al. also found that ε~3~ε~3~ genotype with a frequency of 48% was the most common genotype in their study population.^[@B13]^

Our study includes a small sample size, and statistically signiﬁcant results may occur by chance. It is also unwise to ignore other factors like environment and hereditary conditions that may predispose a person to AD, as there are other genes that may affect the susceptibility to AD. Thus, it will be necessary to assess the relationship between the genetic and environmental factors that influence the risks of AD in other studies.

Conclusion
==========

In conclusion, the results of this study provide further evidence that ε~4~increases the risk of AD. However, a larger study that includes more samples may be necessary to confirm the findings.
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